Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 15Lymphoid 7Breast 5Thoracic 4Genitourinary 4Dermatologic 4Sarcoma 2Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2CNS 2Tumor-Agnostic 1Other neoplasm 1Myeloid 1Gynecologic 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pharmaceutical Preparations × Plasma cell × Clear all
NCT05889221 2026-04-30

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Poitiers University Hospital

Phase NA Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Peking University People's Hospital

Recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡